TAG:
clinical diagnostics market
More IVD Consolidation as Danaher Buys Beckman
By R. Lewis Dark | From the Volume XVIII No. 2 – February 7, 2011 Issue
TODAY IT WAS ANNOUNCED that Danaher Corporation would acquire Beckman Coulter, Inc., in a transaction valued at $5.8 billion. The news was not a surprise, since word had leaked out last December that Beckman’s board of director had engaged Goldman Sachs …
More IVD Consolidation: DPC Sells to Siemens
CEO SUMMARY: It is a significant acquisition, and not just because Diagnostic Products Corporation has a major presence in immunodiagnostics. Siemens Medical Solutions is one of the dominant competitors in radiology. Its willingness to pony up almost $2 billion t…
Proteomic Tests Poised For Clinical Market
By Robert Michel | From the Volume XII No. 12 – August 22, 2005 Issue
CEO SUMMARY: Proteomics-based technology is developing rapidly. The strategic collaboration announced last month between Ciphergen Biosystems and Quest Diagnostics Incorporated is potentially worth $25 million. It is an expensive bet that next-generation proteomics tests soon to enter the…
Sigma-Aldrich, Ivax Diagnostics, i-STAT, Quest Diagnostics, Unilab
By Robert Michel | From the Volume IX No. 8 – June 3, 2002 Issue
SIGMA-ALDRICH SELLS ITS EIA PRODUCT LINE TO IVAX DIAGNOSTICS FOLLOWING ITS DECISION TO EXIT the clinical diagnostics market, Sigma-Aldrich, Inc. has sold its global enzyme immunoassay (EIA) product line to Ivax Diagnostics, Inc., based in Miami, Florida. Th…
Beckman Coulter Positions Itself For Biotech Testing Continuum
By Robert Michel | From the Volume VIII No. 16 – November 26, 2001 Issue
CEO SUMMARY: Here’s a little-known side to diagnostics giant Beckman Coulter Inc. Its efforts to expand into the fields of biomedical R&D and clinical research is a strategic shift designed to give it early access to promising technology that could be introduced into the clinical di…
CURRENT ISSUE
Volume XXXII, No. 1 – January 6, 2025
The Dark Report examines how AI is being used to predict the outcomes of FDA LDT lawsuits. Also, this issue is Part Two of a series about boosting pathology compensation in different settings, including hospitals. Two experienced pathology consultants identify the most effective approaches when negotiating Part A pathology agreements with hospitals and health systems, along with how to use data to bolster these negotiations.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized